DC Chemicals Limited
China
Product Name: AUDA
Price: $Inquiry/25mg $Inquiry/100mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

479413-70-2

479413-70-2 structure

479413-70-2 structure

Name: AUDA
Chemical Name: 12-(1-adamantylcarbamoylamino)dodecanoic acid
CAS Number: 479413-70-2
Molecular Formula: C₂₃H₄₀N₂O₃
Molecular Weight: 392.575
Catalog: Research Areas Inflammation/Immunology
Create Date: 2017-06-22 13:07:03
Modify Date: 2024-01-04 13:14:14
AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively[1]. AUDA has anti-inflammatory activity[2].

Name	12-(1-adamantylcarbamoylamino)dodecanoic acid
Synonyms	12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid HMS2204E15 12-[(Adamantan-1-ylcarbamoyl)amino]dodecanoic acid 12-{[(3s,5s,7s)-Adamantan-1-ylcarbamoyl]amino}dodecanoic acid Dodecanoic acid, 12-[[(tricyclo[3.3.1.1]dec-1-ylamino)carbonyl]amino]- 12-(3-adamantan-1-ylureido)dodecanoic acid Urea-based compound,18 12-[(tricyclo[3.3.1.1]dec-1-ylcarbamoyl)amino]dodecanoic acid AUDA

Description	AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively[1]. AUDA has anti-inflammatory activity[2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
Target	IC50: 18 nM (mouse sEH) and 69 nM (human sEH)[1]
In Vitro	AUDA (0.3-10 μg/mL; 48 hours) dose-dependently suppresses the proliferation of rat VSMCs exposed to PDGF[2]. AUDA (0.3-10 μg/mL; 30 min) dose-dependently upregulats COX-2 expression[2]. AUDA (10, 50 and 100 μM) augments the migratory ability of HCAECs in a dose-dependent manner[3]. AUDA significantly increases the adhesion ability of HCAECs[3]. Cell Proliferation Assay[2] Cell Line: Vascular smooth muscle cell (VSMC) Concentration: 0.3, 1, 3, 10 μg/mL Incubation Time: 48 hours Result: Dose-dependently suppressed the proliferation of rat VSMCs exposed to PDGF. Western Blot Analysis[2] Cell Line: VSMC Concentration: 1, 3, 10, 30 μg/mL Incubation Time: 30 min Result: Dose-dependently upregulated COX-2 expression.
In Vivo	AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels[3]. Animal Model: Male (wild-type) C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g)[3] Dosage: 10 mg/kg Administration: i.p.; 14 days Result: Reduced TNF-α, MMP-9 and IL-1β expression levels.
References	[1]. Morisseau C, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.Biochem Pharmacol. 2002 May 1;63(9):1599-608. [2]. Kim HS, et al. Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.Int J Mol Sci. 2017 Dec 11;18(12). [3]. Dai N, et al. Vascular repair and anti-inflammatory effects of soluble epoxide hydrolase inhibitor.Exp Ther Med. 2019 May;17(5):3580-3588.

Density	1.1±0.1 g/cm3
Boiling Point	592.7±19.0 °C at 760 mmHg
Molecular Formula	C₂₃H₄₀N₂O₃
Molecular Weight	392.575
Flash Point	312.3±21.5 °C
Exact Mass	392.303894
PSA	78.43000
LogP	5.61
Vapour Pressure	0.0±3.6 mmHg at 25°C
Index of Refraction	1.534
Storage condition	-20℃

RIDADR	NONH for all modes of transport

4411-25-0 structure

4411-25-0

693-57-2 structure

693-57-2

~98%

479413-70-2 structure

479413-70-2

Literature: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Patent: WO2006/45119 A2, 2006 ; Location in patent: Page/Page column 44; 52 ; WO 2006/045119 A2

Precursor 2
4411-25-0 693-57-2
DownStream 0